Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical stage pharmaceutical company developing innovative solutions for pain relief that reduce the potential for opioid abuse and overdose, recently announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.
Ensysce Biosciences` PF614-MPAR Enters Final Stage of Phase 1 Study